VALIANT LABORATORIES Financial Statement Analysis
|
||
The Revenues of VALIANT LABORATORIES have increased by 0% YoY .
The Earnings Per Share (EPS) of VALIANT LABORATORIES has increased by 0 YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
VALIANT LABORATORIES Last 5 Annual Financial Results
[BOM: 543998|NSE : VALIANTLAB]
Consolidated | Mar2023 |
---|---|
Revenues | ₹334 Cr |
Expenses | ₹299 Cr |
Operating Profit (Excl OI) | ₹35 Cr |
Other Income | ₹4.86 Cr |
Interest | ₹0.25 Cr |
Depreciation | ₹1.56 Cr |
Profit Before Tax | ₹38 Cr |
Profit After Tax | ₹29 Cr |
Consolidated Net Profit | ₹29 Cr |
Earnings Per Share (Rs) | ₹8.91 |
PAT Margin (%) | 8.68 |
ROE(%) | 28.86 |
ROCE(%) | 24.01 |
Total Debt/Equity(x) | 0.59 |
Key Financials |
||
Market Cap | : | ₹ 616.1 Cr |
Revenue (TTM) | : | ₹ 220.6 Cr |
Net Profit(TTM) | : | ₹ 3.9 Cr |
EPS (TTM) | : | ₹ 0.9 |
P/E (TTM) | : | 158.8 |
Industry Peers & Returns | 1W | 1M | 1Y |
VALIANT LABORATORIES | -4.8% | -14.1% | NA |
SUN PHARMACEUTICAL INDUSTRIES | 2.3% | -0.8% | 60.8% |
CIPLA | 3.5% | 0.7% | 43.8% |
DR REDDYS LABORATORIES | -0.1% | -3.5% | 29.5% |
ZYDUS LIFESCIENCES | 3.1% | 3.8% | 91.8% |
DIVIS LABORATORIES | 2.7% | 3% | 17.1% |
MANKIND PHARMA | 1.1% | -5.5% | 62.9% |
TORRENT PHARMACEUTICALS | 5.1% | 2.9% | 58.8% |
LUPIN | 3.5% | 1% | 113.9% |
VALIANT LABORATORIES Revenues
[BOM: 543998|NSE : VALIANTLAB]
Y-o-Y | 0 % |
5 Yr CAGR | 0 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2023 | ₹334 Cr | - |
VALIANT LABORATORIES Operating Profit
[BOM: 543998|NSE : VALIANTLAB]
Y-o-Y | 0 |
5 Yr CAGR | 0 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2023 | ₹35 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | 0 |
5 Yr CAGR | 0 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2023 | 10.51% | - |
VALIANT LABORATORIES Profit After Tax
[BOM: 543998|NSE : VALIANTLAB]
Y-o-Y | 0 |
5 Yr CAGR | 0 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2023 | ₹29 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | 0 |
5 Yr CAGR | 0 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2023 | 8.68 % | - |
VALIANT LABORATORIES Earnings Per Share (EPS)
[BOM: 543998|NSE : VALIANTLAB]
Y-o-Y | 0 |
5 Yr CAGR | 0 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2023 | ₹8.91 | - |
VALIANT LABORATORIES Return on Capital Employed (ROCE)
[BOM: 543998|NSE : VALIANTLAB]
Y-o-Y | 0 |
5 Yr CAGR | 0 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2023 | 24.01% | - |
VALIANT LABORATORIES Share Price vs Sensex
Current Share Price | : | ₹142.0 |
Current MarketCap | : | ₹ 616.1 Cr |
Updated EOD on | : | May 15,2024 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
VALIANT LABORATORIES | -4.8% |
-14.1% |
|
SENSEX | -0.7% |
-2.7% |
17.8% |
VALIANT LABORATORIES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE IPO | 0.8% | 1.2% | 70.1% |
You may also like the below Video Courses
FAQ about VALIANT LABORATORIES Financials
How the annual revenues of VALIANT LABORATORIES have changed ?
The Revenues of VALIANT LABORATORIES have increased by 0% YoY .
How the Earnings per Share (EPS) of VALIANT LABORATORIES have changed?
The Earnings Per Share (EPS) of VALIANT LABORATORIES has increased by 0 YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs